Thyroid function should be monitored, and levothyroxine doses may need adjustment with significant weight loss
Semaglutide, a GLP-1 receptor agonist marketed as Ozempic, Wegovy, and Rybelsus, has gained widespread attention for its effectiveness in managing type 2 diabetes and promoting weight loss
Heres what we are going to look at: When D64.9 is appropriate and when its not A documentation checklist for cleaner claims Common anemia ICD-10 codes in a quick-reference table Sequencing rules for neoplasm and therapy-related anemia Code-by-scenario breakdowns for iron deficiency, CKD, chronic disease, chemotherapy, and more TLDR D64.9 covers anemia, unspecified
With a high number lost from the placebo group I suspect it was largely due to people not seeing the results they wanted or noting no benefit in terms of appetite reduction thereby informing them they were likely getting the placebo